OSH · Oak Street Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $752.00M | - | $545.70M | $353.10M | $296.70M | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $89.90M | - | $77.00M | $94.90M | $73.10M | - | - | - | - | - |
| Total Operating Expenses | $795.40M | - | $675.90M | $452.40M | $360.50M | - | - | - | - | - |
| D&A | $10.50M | - | $9.10M | $8.40M | $7.80M | - | - | - | $2.50M | - |
| Operating Income | ($43.40M) | - | ($109.40M) | ($112.70M) | ($91.10M) | - | - | - | - | - |
| Interest Expense | $600.0K | - | $600.0K | $1.00M | $200.0K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($45.50M) | - | ($109.40M) | ($98.00M) | ($96.50M) | - | ($59.30M) | ($100.30M) | ($15.40M) | - |
| EPS - Basic | ($0.19) | - | ($0.56) | ($0.44) | - | - | - | - | - | - |
| EPS - Diluted | ($0.19) | - | ($0.56) | ($0.44) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $136.80M | $137.90M | $204.30M | $118.20M | $104.70M | $120.40M | $258.30M | $196.00M | $419.70M | - |
| Accounts Receivable | $1.22B | $894.00M | $833.90M | $825.70M | $697.00M | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $31.10M | $17.10M | $25.90M | $23.50M | $27.90M | - | - | - | - | - |
| Current Assets | $1.62B | $1.36B | $1.42B | $1.41B | $1.39B | - | - | - | - | - |
| Total Assets | $2.32B | $2.05B | $2.10B | $2.06B | $1.90B | - | - | - | - | $0 |
| Current Liabilities | $1.20B | $963.10M | $906.50M | $897.20M | $664.10M | - | - | - | - | - |
| Long-term Debt | $1.01B | $978.60M | $977.00M | $903.60M | - | $901.40M | - | - | - | - |
| Total Liabilities | $2.59B | $2.32B | $2.26B | $2.17B | $1.79B | - | - | - | - | - |
| Stockholders' Equity | ($270.30M) | ($271.10M) | ($160.40M) | ($106.90M) | $51.40M | - | - | - | - | $0 |
| Retained Earnings | ($1.52B) | ($1.47B) | ($1.34B) | ($1.21B) | ($965.30M) | - | - | - | - | - |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($92.70M) | - | - | - | ($91.20M) | - | - | - | ($36.90M) | - |
| Investing Cash Flow | $46.90M | - | - | - | $94.20M | - | - | - | ($3.40M) | - |
| Financing Cash Flow | $43.50M | - | - | - | $1.90M | - | - | - | $224.40M | - |
| CapEx | $17.00M | - | - | - | $19.80M | - | - | - | $3.40M | - |
| Free Cash Flow | ($109.70M) | - | - | - | ($111.00M) | - | - | - | ($40.30M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -5.8% | - | -20.0% | -31.9% | -30.7% | - | - | - | - | - |
| EBITDA margin | -4.4% | - | -18.4% | -29.5% | -28.1% | - | - | - | - | - |
| Net margin | -6.1% | - | -20.0% | -27.8% | -32.5% | - | - | - | - | - |
| Free cash flow margin | -14.6% | - | - | - | -37.4% | - | - | - | - | - |
| FCF / Net income | 2.41 | - | - | - | 1.15 | - | - | - | 2.62 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 12.0% | - | 14.1% | 26.9% | 24.6% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.0% | - | -5.2% | -4.7% | -5.1% | - | - | - | - | - |
| Return on equity | 16.8% | - | 68.2% | 91.7% | -187.7% | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.35 | 1.41 | 1.56 | 1.57 | 2.10 | - | - | - | - | - |
| Quick ratio | 1.35 | 1.41 | 1.56 | 1.57 | 2.10 | - | - | - | - | - |
| Cash ratio | 0.11 | 0.14 | 0.23 | 0.13 | 0.16 | - | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | -3.72 | -3.61 | -6.09 | -8.45 | - | - | - | - | - | - |
| Debt / Assets | 0.43 | 0.48 | 0.47 | 0.44 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -72.3x | - | -182.3x | -112.7x | -455.5x | - | - | - | - | - |
| Equity multiplier | -8.59 | -7.58 | -13.10 | -19.30 | 37.03 | - | - | - | - | - |
| Liabilities / Assets | 1.11 | 1.13 | 1.07 | 1.05 | 0.94 | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.32 | - | 0.26 | 0.17 | 0.16 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 590d | - | 558d | 854d | 857d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 153.5% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 52.4% | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | 52.8% | - | -84.5% | 2.3% | -526.6% | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 1.2% | - | - | - | -175.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$519.70M totalCapitated Revenue$506.70M · 97.5%
Other Revenue$6.50M · 1.3%
Care Coordination Revenue$5.40M · 1.0%
Fee For Service Revenue$1.10M · 0.2%
Peer comparison
Same SIC group: Services-Health Services
Comparing Oak Street Health against the 5 most active filers in the same SIC group.